ID   WM1552C
AC   CVCL_6472
SY   WM-1552C; WM 1552C; WM-1552; WM1552; EST73
DR   CLO; CLO_0009614
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2808
DR   BioSample; SAMN03471792
DR   cancercelllines; CVCL_6472
DR   Cell_Model_Passport; SIDM00976
DR   Cosmic; 886833
DR   Cosmic; 1047652
DR   Cosmic; 1303064
DR   Cosmic; 1995664
DR   Cosmic; 2159426
DR   Cosmic; 2163802
DR   Cosmic-CLP; 1299078
DR   DepMap; ACH-002205
DR   EGA; EGAS00001000978
DR   ESTDAB; ESTDAB-073
DR   GDSC; 1299078
DR   GEO; GSM156020
DR   GEO; GSM186469
DR   GEO; GSM186470
DR   GEO; GSM555134
DR   GEO; GSM555186
DR   GEO; GSM952582
DR   GEO; GSM1670577
DR   IARC_TP53; 26079
DR   LINCS_HMS; 50568
DR   LINCS_LDP; LCL-1261
DR   PharmacoDB; WM1552C_1668_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_6472
DR   Rockland; WM1552C-01-0001
DR   Wikidata; Q54994175
RX   PubMed=11123321;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=19340423;
RX   PubMed=21343389;
RX   PubMed=23851445;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   HLA typing: A*03:01,02:01; B*13:02,07:02; C*07:02,06:02; DPB1*04:01,04:02; DQB1*06:02,02:01; DRB1*15:01,ND (PubMed=15592718).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; Wistar).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; Cosmic-CLP; DepMap; Wistar).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.634+5G>T; ClinVar=VCV001338631; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.24%; East Asian, North=0%; East Asian, South=1.1%; South Asian=2.39%; European, North=72.29%; European, South=23.98% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D13S317: 12->11,12.
CC   Discontinued: ATCC; CRL-2808; true.
CC   Derived from site: In situ; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11,12 (Wistar)
ST   D13S317: 12 (Cosmic-CLP; ESTDAB)
ST   D13S317: 12,14 (ATCC)
ST   D16S539: 9,11
ST   D18S51: 15
ST   D19S433: 14
ST   D21S11: 30
ST   D2S1338: 24,25
ST   D3S1358: 14
ST   D5S818: 12
ST   D7S820: 10,11,12 (ATCC)
ST   D7S820: 10,12 (Cosmic-CLP; ESTDAB; Wistar)
ST   D8S1179: 11,12
ST   FGA: 22
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   PubMed=11123321; DOI=10.4049/jimmunol.166.1.432;
RA   Li J., Pereira S., Van Belle P., Tsui P., Elder D.E., Speicher D.W.,
RA   Deen K., Linnenbach A., Somasundaram R., Swoboda R.K., Herlyn D.;
RT   "Isolation of the melanoma-associated antigen p23 using antibody phage
RT   display.";
RL   J. Immunol. 166:432-438(2001).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//